Overview / Abstract: |
Target Audience This educational program is directed toward medical oncologists/hematologists, and other oncology HCPs involved in the treatment of multiple myeloma. Advanced practitioners, nurses, pharmacists, and other healthcare professionals interested in multiple myeloma will be invited to participate. Program Overview This Expert Illustrations and CommentariesTMonline activity is a video-based program in which 2 experts discuss emerging treatments in multiple myeloma (MM), namely B-cell directed maturation antigen (BCMA) therapy. In this activity, the faculty focus on treatments for both newly diagnosed (ND) and relapsed/refractory (RR) multiple myeloma. Their discussion is enriched with the addition of video animations to illustrate the mechanism of action of various BCMA therapies, including antibody-drug conjugates (ADC), bispecific T-cell engagers (BiTE), and chimeric antigen receptor (CAR) T-cell agents. This unique format is designed to help clinicians understand the mechanism of emerging agents to identify best practices in the treatment of MM and to improve outcomes for their patients with this disease. Learning Objectives Upon completion of this activity, participants should be better able to: Explain the rationale for targeting BCMA in R/R MM and the mechanisms of action for therapeutic agents acting through BCMA |
Expiration |
Dec 23, 2022 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
1.0 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty FACULTY_NAME FACULTY_NAME |
Sponsors / Supporters / Grant Providers |
Pfizer Inc. |
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME., Multiple Myeloma Free CE CME |